Suppr超能文献

相似文献

2
Deletion of cd39/entpd1 results in hepatic insulin resistance.
Diabetes. 2008 Sep;57(9):2311-20. doi: 10.2337/db07-1265. Epub 2008 Jun 20.
3
Disordered purinergic signaling inhibits pathological angiogenesis in cd39/Entpd1-null mice.
Am J Pathol. 2007 Oct;171(4):1395-404. doi: 10.2353/ajpath.2007.070190. Epub 2007 Sep 6.
4
CD39 limits P2X7 receptor inflammatory signaling and attenuates sepsis-induced liver injury.
J Hepatol. 2017 Oct;67(4):716-726. doi: 10.1016/j.jhep.2017.05.021. Epub 2017 May 26.
6
Disordered pancreatic inflammatory responses and inhibition of fibrosis in CD39-null mice.
Gastroenterology. 2008 Jan;134(1):292-305. doi: 10.1053/j.gastro.2007.10.030. Epub 2007 Oct 25.
8
CD39-mediated ATP-adenosine signalling promotes hepatic stellate cell activation and alcoholic liver disease.
Eur J Pharmacol. 2021 Aug 15;905:174198. doi: 10.1016/j.ejphar.2021.174198. Epub 2021 May 24.
9
Purinergic dysregulation in pulmonary hypertension.
Am J Physiol Heart Circ Physiol. 2016 Jul 1;311(1):H286-98. doi: 10.1152/ajpheart.00572.2015. Epub 2016 May 20.
10
CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice.
Gastroenterology. 2010 Sep;139(3):1030-40. doi: 10.1053/j.gastro.2010.05.007. Epub 2010 Jun 25.

引用本文的文献

1
Antisense to human CD39 dysregulates immune metabolism in inflammatory bowel disease.
Cell Mol Immunol. 2025 May 26. doi: 10.1038/s41423-025-01295-6.
4
Regulatory role of CD39 and CD73 in tumor immunity.
Future Oncol. 2024;20(19):1367-1380. doi: 10.2217/fon-2023-0871. Epub 2024 Apr 23.
5
Platelets induce CD39 expression in tumor cells to facilitate tumor metastasis.
Br J Cancer. 2024 May;130(9):1542-1551. doi: 10.1038/s41416-024-02640-8. Epub 2024 Mar 9.
6
CD39 tumor infiltrating T cells from colorectal cancers exhibit dysfunctional phenotype.
Am J Cancer Res. 2024 Feb 15;14(2):585-600. doi: 10.62347/IZEN3736. eCollection 2024.
7
Purinergic pathways and their clinical use in the treatment of acute myeloid leukemia.
Purinergic Signal. 2024 Mar 6. doi: 10.1007/s11302-024-09997-8.
8
Adenosine A2A receptor is a tumor suppressor of NASH-associated hepatocellular carcinoma.
Cell Rep Med. 2023 Sep 19;4(9):101188. doi: 10.1016/j.xcrm.2023.101188.
9
Review immune response of targeting CD39 in cancer.
Biomark Res. 2023 Jun 7;11(1):63. doi: 10.1186/s40364-023-00500-w.
10
Emerging roles of purinergic signaling in anti-cancer therapy resistance.
Front Cell Dev Biol. 2022 Sep 19;10:1006384. doi: 10.3389/fcell.2022.1006384. eCollection 2022.

本文引用的文献

1
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development.
Nature. 2011 Nov 9;479(7374):547-51. doi: 10.1038/nature10599.
2
Metabolism, genomics, and DNA repair in the mouse aging liver.
Curr Gerontol Geriatr Res. 2011;2011:859415. doi: 10.1155/2011/859415. Epub 2011 Apr 6.
5
The ER UDPase ENTPD5 promotes protein N-glycosylation, the Warburg effect, and proliferation in the PTEN pathway.
Cell. 2010 Nov 24;143(5):711-24. doi: 10.1016/j.cell.2010.10.010. Epub 2010 Nov 11.
6
CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice.
Gastroenterology. 2010 Sep;139(3):1030-40. doi: 10.1053/j.gastro.2010.05.007. Epub 2010 Jun 25.
8
Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth.
Sci Signal. 2009 Nov 17;2(97):ra73. doi: 10.1126/scisignal.2000431.
9
LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer.
Mol Cancer Ther. 2009 Mar;8(3):626-35. doi: 10.1158/1535-7163.MCT-08-1049. Epub 2009 Mar 10.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验